In Vitro Diagnostics - LATAM

LATAM

Highlights

The In Vitro Diagnostics market market in LATAM is set to achieve a significant milestone, with projected revenue of US$7.14bn in 2024.
This market is expected to witness steady growth, with an annual growth rate (CAGR 2024-2029) of 2.96%.
As a result, the market volume is estimated to reach US$8.27bn by 2029.
In comparison to other regions, the United States is anticipated to generate the highest revenue in the In Vitro Diagnostics market market, with an impressive US$30.10bn in 2024.
In LATAM, there is a growing demand for In Vitro Diagnostics as the region focuses on improving healthcare infrastructure.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The In Vitro Diagnostics market in LATAM is experiencing significant growth due to several factors. Customer preferences for accurate and timely diagnostic tests, along with advancements in technology and an increasing focus on preventive healthcare, are driving the demand for in vitro diagnostics in the region. Customer preferences in LATAM are shifting towards in vitro diagnostics as they offer several advantages over traditional diagnostic methods. These tests provide accurate and reliable results, allowing for early detection and treatment of diseases. Additionally, in vitro diagnostics are less invasive and require smaller sample sizes, making them more convenient for patients. As a result, there is a growing demand for in vitro diagnostic tests in the region. Trends in the market show an increasing adoption of point-of-care testing (POCT) devices in LATAM. POCT devices enable rapid and on-site testing, eliminating the need for samples to be sent to a laboratory. This trend is driven by the need for immediate results, particularly in emergency situations or in remote areas with limited access to healthcare facilities. POCT devices also offer cost savings as they reduce the need for multiple healthcare visits and laboratory tests. Another trend in the market is the growing demand for molecular diagnostics. Molecular diagnostic tests enable the detection and analysis of genetic material, allowing for more accurate diagnosis and personalized treatment plans. This trend is driven by the increasing prevalence of chronic diseases and the need for targeted therapies. Molecular diagnostics also play a crucial role in infectious disease testing, particularly in the context of emerging diseases such as COVID-19. Local special circumstances in LATAM, such as the presence of a large underserved population and limited healthcare infrastructure in certain regions, contribute to the growth of the in vitro diagnostics market. These circumstances create a need for accessible and affordable diagnostic tests that can be performed outside of traditional healthcare settings. In vitro diagnostics provide a solution to these challenges by offering portable and easy-to-use testing devices. Underlying macroeconomic factors, such as increasing healthcare expenditure and government initiatives to improve healthcare infrastructure, are also driving the growth of the in vitro diagnostics market in LATAM. Governments in the region are investing in healthcare systems and implementing policies to promote preventive healthcare and early disease detection. This creates a favorable environment for the adoption of in vitro diagnostics. In conclusion, the In Vitro Diagnostics market in LATAM is experiencing significant growth due to customer preferences for accurate and timely diagnostic tests, the adoption of point-of-care testing devices, the demand for molecular diagnostics, local special circumstances, and underlying macroeconomic factors. These factors are driving the demand for in vitro diagnostics in the region and are expected to continue shaping the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Explore more high-quality data on related topic

Medical technology industry - statistics & facts

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.